Compare Arqit Quantum Inc (ARQQ) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Arqit Quantum Inc vs Smith & Nephew plc — how do they compare? Arqit Quantum Inc trades at $23.71 (market cap $424.79M), while Smith & Nephew plc trades at $29.86 (market cap $12.54B). The key difference: Smith & Nephew plc is far larger — about 29.5× Arqit Quantum Inc's market cap, and Smith & Nephew plc pays a 2.65% dividend while Arqit Quantum Inc pays none. Which is the better fit depends on your goals.
| ARQQ | SNN | |
|---|---|---|
Market Cap | $424.79M | $12.54B |
Sector | Technology | Health |
52-Week High | $58.27 | $38.70 |
52-Week Low | $11.78 | $28.73 |
Enterprise Value | $398.10M | $15.57B |
Dividend Yield | — | 2.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARQQ trades at $23.70, up 4.82% today, with a bullish technical signal from moving averages and ADX. The stock shows extreme valuation metrics with a P/S of 352.9 and P/B of 14.9, while fundamentals reveal severe losses: Q1 2026 EPS missed at -$1.99, net income margin is -4,508.1%, and revenue remains minimal at $530K for 2025. Recent news highlights a proof of concept with nLighten and 829% YoY revenue growth in H1 FY26, signaling potential commercial traction in quantum-safe encryption.
Outlook hinges on scaling revenue to justify valuation, with risks from persistent cash burn and high SG&A. Analyst sentiment is split 50/50 buy/hold, reflecting optimism for government/telecom contracts against financial distress. The stock faces volatility near resistance at $25, requiring sustained growth to support bullish momentum.
Smith & Nephew (SNN) trades at $29.76, down 1.06% with bearish technical signals. The company shows improving fundamentals with revenue growth from $5.8B to $6.2B and net income margin expanding to 10.08% in 2025. Recent Q2 2026 earnings beat expectations but the company lowered full-year revenue guidance from 6% to 4% growth due to U.S. Orthopaedics weakness.
While valuation multiples appear reasonable (P/E 20.41, EV/EBITDA 9.9), the stock faces headwinds from mixed earnings performance and cautious analyst sentiment. The primary investment case hinges on execution in robotics and wound care segments offsetting orthopedic challenges, with downside risk from continued U.S. market softness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Arqit Quantum Inc
Arqit Quantum provides advanced cybersecurity software that uses symmetric key agreement technology. Its solutions protect networked devices and data against current and future cyber threats, including quantum attacks.
Read more on ARQQ →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
